FIGURE 4:

Representative renal protein expression (top, n = 4–5 per group, two representative bands per animal shown) and average quantification per group (bottom) of TGF-β, smad-4, MMP-2, TIMP-1, cleaved Caspase 3 and 8 and phosphorylated proliferating cell nuclear antigen (p-PCNA) in normal, RVD and RVD + macitentan-treated kidneys at 10 weeks. Treatment with macitentan attenuated fibrotic and apoptotic activity in the stenotic kidney, indicating a reduction in kidney injury (*P < 0.05 versus normal, ^P = 0.06 versus normal, ^†P < 0.05 versus RVD).